MEXICOS STEELMAKERS LINE UP TO ORDER HYL-III

被引：0
|
作者：
不详
机构：
来源：
E&MJ-ENGINEERING AND MINING JOURNAL | 1980年 / 181卷 / 12期
关键词：
D O I：
暂无
中图分类号：
TD [矿业工程];
学科分类号：
0819 ;
摘要：
引用
收藏
页码：78 / &
相关论文
共 48 条
  • [31] Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
    Powles, T.
    Burotto, M.
    Escudier, B.
    Apolo, A. B.
    Bourlon, M. T.
    Shah, A. Y.
    Suarez, C.
    Porta, C.
    Barrios, C. H.
    Richardet, M.
    Gurney, H.
    Kessler, E. R.
    Tomita, Y.
    Bedke, J.
    George, S.
    Scheffold, C.
    Wang, P.
    Fedorov, V.
    Motzer, R. J.
    Choueiri, T. K.
    ESMO OPEN, 2024, 9 (05)
  • [32] E-commerce and the information market -: Orchestrating online transactions between suppliers and customers, infomediaries walk a fine line creating services, controlling costs, and not winding up as order-takers for larger entities.
    Grover, V
    Teng, JTC
    COMMUNICATIONS OF THE ACM, 2001, 44 (04) : 79 - 86
  • [33] CF-HiZELS, an ∼10 deg2 emission-line survey with spectroscopic follow-up: Hα, [O III] plus Hβ and [O II] luminosity functions at z=0.8, 1.4 and 2.2
    Sobral, D.
    Matthee, J.
    Best, P. N.
    Smail, I.
    Khostovan, A. A.
    Milvang-Jensen, B.
    Kim, J. -W.
    Stott, J.
    Calhau, J.
    Nayyeri, H.
    Mobasher, B.
    MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY, 2015, 451 (03) : 2303 - 2323
  • [34] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies
    Martorell, C.
    Ramgopal, M.
    Hagins, D.
    Osiyemi, O.
    Arribas, J. R.
    Berhe, M.
    Yazdanpanah, Y.
    Orkin, C.
    Santiago, L.
    Rosero, C.
    Unger, N.
    Liu, H.
    Rogers, R.
    Hindman, J. T.
    Wurapa, A.
    HIV MEDICINE, 2025,
  • [35] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [36] Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
    Tannir, N. M.
    Albiges, L.
    Mcdermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Barthelemy, P.
    Plimack, E. R.
    Portat, C.
    George, S.
    Donskov, F.
    Atkins, M. B.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M. -o.
    Barrios, C.
    Tomita, Y.
    Castellano, D.
    Gruenwald, V.
    Rini, B. I.
    Jiang, R.
    Desilva, H.
    Fedorov, V.
    Lee, C. -w.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1026 - 1038
  • [37] High resolution specific heat experiments on the vortex melting line in MBa2Cu3Ox (M=Y, Dy and Eu) crystals: Observation of first- and second-order transitions up to 16T
    Roulin, M
    Revaz, B
    Junod, A
    Erb, A
    Walker, E
    PHYSICS AND MATERIALS SCIENCE OF VORTEX STATES, FLUX PINNING AND DYNAMICS, 1999, 356 : 489 - 504
  • [38] Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year follow-up results of a phase III trial of the east German study group hematology and oncology (OSHO#39).
    Herold, Michael
    Haas, Antje
    Srock, Stephanie
    Neser, Sabine
    Al Ali, Kathrin H.
    Neubauer, Andreas
    Doelken, Gottfried
    Naumann, Ralph
    Fietz, Thomas
    Freund, Mathias
    Rohrberg, Robert
    Hoeffken, Klaus
    Franke, Astrid
    Ittel, Thomas H.
    Kettner, Erika
    BLOOD, 2006, 108 (11) : 147A - 147A
  • [39] Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up
    Yoon, Harry H.
    Kato, Ken
    Raymond, Eric
    Hubner, Richard
    Shu, Yongqian
    Pan, Yueyin
    Jiang, Yi
    Zhang, Jingdong
    Park, Sook Ryun
    Kojima, Takashi
    Lin, Chen-Yuan
    Wyrwicz, Lucjan S.
    Tougeron, David
    Ishihara, Ryu
    Li, Liyun
    Wu, Hongqian
    Peng, Yanyan
    Yan, Shican
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Dual immune checkpoint inhibition in metastatic renal cell carcinoma Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
    Schmidinger, M.
    Shariat, S. F.
    Fajkovic, H.
    ESMO OPEN, 2021, 6 (01)
12345